Previous close | 0.9500 |
Open | 1.0000 |
Bid | 0.3000 |
Ask | 0.4500 |
Strike | 4.00 |
Expiry date | 2024-08-16 |
Day's range | 0.9500 - 1.0000 |
Contract range | N/A |
Volume | |
Open interest | 282 |
Amidst a significant net loss increase, Omeros Corp navigates through promising drug trials and strategic royalty milestones.
SEATTLE, May 15, 2024--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2024, which include: